test
document.getElementById("video").style.height=document.getElementById("video").scr
Prof. Anna Sureda, President of EBMT, on China-Europe Collaboration and the Future of Cellular Therapy | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy
Editor’s Note:The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of the…
“50 Years of Hematopoietic Stem Cell Transplantation”
We were honored to hear from Professor Xiaojun Huang of Peking University People’s Hospital and the Peking University Institute of Hematology, who shared a comprehensive reflection on the global evolution of hematopoietic stem cell transplantation (HSCT).
From Dr. Edward Donnall Thomas' foundational work to the creation of the Beijing Protocol, Professor Huang spotlighted how China’s innovations—including non–T-cell-depleted haploidentical transplantation—are transforming clinical practice worldwide.
Can We Prevent CAR T-Associated Neurotoxicity Without Compromising Efficacy?
At EBMT25, Dr. Janaki Manoja Vinnakota presented compelling data on the role of microglial TAK1 activation in the development of CAR T cell therapy-associated neurotoxicity (ICANS). In her presentation titled…
EAU25 Interview Highlights | Prof. Samson Chan & Prof. Junlong Zhuang on PARPi in mHSPC
At the 2025 EAU Congress, Prof. Junlong Zhuang (Nanjing Drum Tower Hospital) and Prof. Samson Chan (Department of Surgery, Tuen Mun Hospital, Hong Kong) sat down with Urology Frontier to discuss new insights from the Phase II PROact study.
The study evaluated a triple combination of olaparib + abiraterone + prednisone in metastatic hormone-sensitive prostate cancer (mHSPC). According to the professors, early data show promising efficacy and manageable safety—suggesting PARP inhibitors may soon have a role beyond mCRPC in the prostate cancer treatment landscape.
A potential step forward in precision therapy for prostate cancer.
Watch the full interview now to hear their perspectives on the evolving role of PARPi in mHSPC.
New Hope for Drug-Resistant TB: MBLA Outperforms Xpert in Predicting Treatment Success
A new study published in the Journal of Infection reveals that the Molecular Bacterial Load Assay (MBLA) provides a faster and more accurate way to monitor treatment response in patients with pre-XDR/XDR-TB, compared to the widely used GeneXpert Ultra MTB/RIF test.
Xinghai Forum: Professors Yang Zhang and Kejing Zhang Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer
Xinghai Forum: Professors Yang Zhang and Kejing Zhang Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer Editor's Note: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have brought transformative breakthroughs to…
Professors Bing Chen and Lijuan Chen’s Team: FUMANBA-2 Study Opens New Horizons for Treating High-Risk Newly Diagnosed Multiple Myeloma
The 29th Annual Congress of the European Hematology Association (EHA) took place from June 13 to June 16, 2024, in Madrid, Spain. On the afternoon of June 15, local time, Professor Bing Chen from Nanjing Drum Tower Hospital affiliated with Nanjing University Medical School presented the latest data from the FUMANBA-2 study in an oral report at the main venue of the EHA conference, attracting global medical attention. This study, co-led by Professor Bing Chen and Professor Lijuan Chen from Jiangsu Province People's Hospital, utilizes an all-human BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy to bring new hope to high-risk newly diagnosed multiple myeloma (NDMM) patients, heralding a new chapter in multiple myeloma treatment. "Oncology Frontier - Hematology Frontier" invited Professor Bing Chen to provide an in-depth interpretation of the study background, design, and results of the FUMANBA-2 study for our readers.
Celebrating World Breastfeeding Week!
Celebrating World Breastfeeding Week! From August 1st to 7th, we honor and support the beautiful journey of breastfeeding. Let's join hands to promote the importance of breastfeeding for both mothers and babies. It's more than just nourishment—it's about bonding, health, and giving our little ones the best start in life
ASCO GI 2025 | Dr. Zhenyu Lin: Short-Course Radiotherapy Plus Targeted, Immuno-, and Chemotherapy for High-Risk LA
Editor's Note: The neoadjuvant treatment landscape for locally advanced rectal cancer (LARC) continues to evolve, with emerging research indicating that incorporating immunotherapy can significantly enhance the pathological complete response (pCR)…